Pozanicline (ABT-089) is a drug developed by Abbott, which acts as a partial agonist at neural nicotinic acetylcholine receptors. It is subtype-selective, binding primarily to the α4β2 and also α6β2 subtypes. It has nootropic and neuroprotective effects, and animal studies suggested that it might be useful for the treatment of ADHD. Subsequent human trials have shown ABT-089 to both be effective for this application, and also to have particularly low tendency to cause side effects compared to other drugs in the class, making it a promising candidate for clinical development.




This page contains text from Wikipedia, the Free Encyclopedia - http://en.wikipedia.org/wiki/Pozanicline

This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.









×